Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial
Authors' conclusion
Combined with intensive lifestyle interventions, a 26-week treatment with exenatide was not demonstrated superior to placebo to treat craniopharyngioma-related obesity.
Study context
- Population
- Adults with craniopharyngioma-related obesity (BMI > 30 kg/m²) without sign of craniopharyngioma recurrence in the past year; 11 French University Hospital Centers
- Comparison
- Exenatide vs placebo
- Primary endpoint
- Mean change in body weight, ITT population
- Follow-up
- Week 26
Methodological detailsdouble-blind, multicenter, superiority, two parallel arms
- Double-blind
- Multicenter
- Superiority
- Two parallel arms
Primary result
Change in body weight from baseline
Adjusted mean treatment difference
−3.1 kg
95% CI −7.0 to 0.7
P = 0.11
Change by group
Exenatide
−3.8
mean · SD 4.3 · kg
Placebo
−1.6
mean · SD 3.8 · kg
Between Exenatide and Placebo
adjusted mean treatment difference −3.1 kg (95% CI −7.0 to 0.7); P = 0.11
As reported in the abstract
Secondary outcomes
| Outcome | Estimated treatment difference (95% CI) | |
|---|---|---|
| Hunger score, change from baseline · week 26Higher reduction of hunger score with exenatide | −2.3 (−4.5 to −0.2) | |
| −6−4−202Difference (linear scale) |
All other secondary outcomes
- All other outcomes did not significantly differ between groups
Safety
Adverse events
Events Exenatide 108 · Placebo 54
Adverse events
- Adverse events more common with exenatide vs placebo
Original publication
Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial. Eur J Endocrinol. Published 12 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →